Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients

被引:7
作者
de Marinis, Giulia Berti [1 ]
Novello, Stefano [2 ]
Ferrari, Silvia [2 ]
Barzon, Isabella [2 ]
Cortella, Irene [2 ]
Businaro, Maria Antonietta [2 ]
Fabris, Fabrizio [2 ]
Lombardi, Anna Maria [2 ]
机构
[1] Univ Hosp Padova, Emergency Dept, Via Giustiniani 2, I-35128 Padua, Italy
[2] Univ Padua, Dept Med, Internal Med, Padua, Italy
关键词
TTP; ADAMTS13; activity; Epilepsy; Thrombotic microangiopathy; FACTOR-CLEAVING PROTEASE; THROMBOCYTOPENIC PURPURA; ANTI-ADAMTS13; ANTIBODIES; DIAGNOSIS; OUTCOMES;
D O I
10.1007/s11239-016-1395-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Differential diagnosis between thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies (TMA) is usually difficult because of frequently overlapping clinical presentations. Severely depressed ADAMTS13 activity (< 10 %) seems distinctive for TTP because of its pathogenetic role. However a long debate exists in the literature about its sensibility and specificity. Our aim was to search for clinical differences between TMA patients referred to our laboratory, comparing them for protease activity < 10 versus aeyen10 %. ADAMTS13 activity aeyen10 % patients (n = 73) showed a higher prevalence of drug- (p = 0.005) and cancer-associated (p < 0.001) TMA. Mean platelet count and renal dysfunction prevalence was lower (p < 0.001), while neurological impairment was more frequent (p = 0.001) in the < 10 % ADAMTS13 activity group (n = 109), confirming previous literature findings. When taken neurological manifestations singularly, epilepsy (p = 0.04), focal motor deficit (p < 0.001) and cranial nerve palsy (p = 0.007) were more frequent in the < 10 % activity group. In our case series, a < 10 % ADAMTS13 activity depicts a group of patients with clinical features similar to TTP patients. Focal motor impairment or epileptic manifestations could further address toward a TTP diagnosis. Studies about treatment efficacy and follow-up are advised to determine whether laboratory findings can guide therapeutic decisions.
引用
收藏
页码:586 / 592
页数:7
相关论文
共 23 条
  • [1] Use of the ADAMTS13 Activity Assay Improved the Accuracy and Efficiency of the Diagnosis and Treatment of Suspected Acquired Thrombotic Thrombocytopenic Purpura
    Barrows, Brad D.
    Teruya, Jun
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2014, 138 (04) : 546 - 549
  • [2] Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative
    Bendapudi, Pavan K.
    Li, Ang
    Hamdan, Ayad
    Uhl, Lynne
    Kaufman, Richard
    Stowell, Christopher
    Dzik, Walter
    Makar, Robert S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (05) : 836 - 844
  • [3] Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience
    Coppo, Paul
    Schwarzinger, Michael
    Buffet, Marc
    Wynckel, Alain
    Clabault, Karine
    Presne, Claire
    Poullin, Pascale
    Malot, Sandrine
    Vanhille, Philippe
    Azoulay, Elie
    Galicier, Lionel
    Lemiale, Virginie
    Mira, Jean-Paul
    Ridel, Christophe
    Rondeau, Eric
    Pourrat, Jacques
    Girault, Stephane
    Bordessoule, Dominique
    Saheb, Samir
    Ramakers, Michel
    Hamidou, Mohamed
    Vernant, Jean-Paul
    Guidet, Bertrand
    Wolf, Martine
    Veyradier, Agnes
    [J]. PLOS ONE, 2010, 5 (04):
  • [4] Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura
    Ferrari, S.
    Knoebl, P.
    Kolovratova, V.
    Plaimauer, B.
    Turecek, P. L.
    Varadi, K.
    Rottensteiner, H.
    Scheiflinger, F.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (01) : 156 - 158
  • [5] Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
    Furlan, M
    Robles, R
    Galbusera, M
    Remuzzi, G
    Kyrle, PA
    Brenner, B
    Krause, M
    Scharrer, I
    Aumann, V
    Mittler, U
    Solenthaler, M
    Lämmle, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) : 1578 - 1584
  • [6] Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?
    George, James N.
    [J]. TRANSFUSION, 2015, 55 (01) : 11 - 13
  • [7] Survival and relapse in patients with thrombotic thrombocytopenic purpura
    Hovinga, Johanna A. Kremer
    Vesely, Sara K.
    Terrell, Deirdra R.
    Laemmle, Bernhard
    George, James N.
    [J]. BLOOD, 2010, 115 (08) : 1500 - 1511
  • [8] FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay
    Kokame, K
    Nobe, Y
    Kokubo, Y
    Okayama, A
    Miyata, T
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) : 93 - 100
  • [9] Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
    Levy, GG
    Nichols, WC
    Lian, EC
    Foroud, T
    McClintick, JN
    McGee, BM
    Yang, AY
    Siemieniak, DR
    Stark, KR
    Gruppo, R
    Sarode, R
    Shurin, SB
    Chandrasekaran, V
    Stabler, SP
    Sabio, H
    Bouhassira, EE
    Upshaw, JD
    Ginsburg, D
    Tsai, HM
    [J]. NATURE, 2001, 413 (6855) : 488 - 494
  • [10] Presence of anti-ADAMTS13 antibodies in obesity
    Lombardi, Anna M.
    Fabris, Roberto
    Scarda, Alessandro
    Zanato, Veronica
    Dal Pra, Chiara
    Scarparo, Pamela
    Vettore, Silvia
    Granzotto, Marnie
    De Marinis, Giulia Berti
    Foletto, Mirto
    Serra, Roberto
    Sartori, Maria T.
    Plebani, Mario
    Fabris, Fabrizio
    Vettor, Roberto
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 (11) : 1197 - 1204